Introduction
============

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease. IPF predominantly affects elderly men. Patients with IPF usually present with exertional dyspnea, dry cough and inspiratory bibasilar Velcro-like crackles on lung auscultation. At present, high-resolution computed tomography is the most important diagnostic tool for IPF, which typically presents with usual interstitial pneumonia pattern ([@b1-ijmm-43-04-1643],[@b2-ijmm-43-04-1643]). IPF is a lethal lung disease. The prognosis of IPF is poorer compared with a number of types of cancer ([@b3-ijmm-43-04-1643]), with an estimated median survival of 3-5 years if untreated ([@b2-ijmm-43-04-1643]). The incidence of IPF, hospitalization rates and mortality due to IPF have increased during previous years, suggesting an increasing global burden of this disease ([@b4-ijmm-43-04-1643]-[@b6-ijmm-43-04-1643]).

The pathogenesis of IPF remains largely unknown. Data from observational studies suggest that cigarette smoking, air pollution ([@b7-ijmm-43-04-1643]), environmental exposure ([@b8-ijmm-43-04-1643]), chronic viral infection ([@b9-ijmm-43-04-1643]) and esophageal reflux ([@b10-ijmm-43-04-1643]) predispose individuals to IPF ([@b4-ijmm-43-04-1643]). There is also increasing evidence for genetic predisposition to IPF: Recent genome-wide association studies identified that several genetic variants, primarily involved in epithelial cell-cell adhesion and integrity, the innate immune response, host defense and DNA repair, are associated with increased risk of IPF ([@b11-ijmm-43-04-1643]-[@b13-ijmm-43-04-1643]). These together indicate that gene-environmental interactions serve important roles in the pathogenesis of IPF. In genetically predisposed individuals, repetitive environmental exposures lead to an aberrant injury-remodeling process ([@b14-ijmm-43-04-1643]). Activated lung epithelial cells produce pro-fibrotic growth factors, chemokines and other mediators, resulting in abnormal wound healing characterized by mesenchymal transition of epithelial cells, activation and differentiation of fibroblasts and myofibroblasts. These fibroblasts and myofibroblasts secrete excessive amounts of extracellular matrix proteins including fibrillary collagens, vimentin and fibronectin ([@b15-ijmm-43-04-1643]), contributing to the destruction of lung architecture by progressive scarring.

It is hypothesized that fibroblasts have a number of functions that may affect the development and progression of IPF ([@b16-ijmm-43-04-1643]). Although previous studies have described the differences between IPF and normal lung fibroblasts ([@b17-ijmm-43-04-1643]-[@b21-ijmm-43-04-1643]), the knowledge concerning the cellular and molecular mechanisms associated with fibroblasts in IPF remains limited, and their specific roles requires additional investigation ([@b16-ijmm-43-04-1643],[@b22-ijmm-43-04-1643]).

For an improved understanding of the roles fibroblasts serve in the pathogenesis of IPF, the present study used a next generation sequencing (NGS) platform and a step-wise bioinformatic approach to analyze the expression levels of mRNAs and microRNAs (miRNAs) and their interactions in IPF fibroblasts compared with normal lung fibroblasts. The aims of the present study were to identify the top differentially expressed genes and subsequently elucidate the function of these dysregulated genes, and to explore potential miRNA-mRNA interactions in IPF fibroblasts.

Materials and methods
=====================

Study design
------------

The study design is summarized in [Fig. 1](#f1-ijmm-43-04-1643){ref-type="fig"}. Firstly, cell cultures of the IPF fibroblasts and healthy lung fibroblasts were generated. Then, total RNA of the fibroblasts were extracted and sent for RNA and small RNA sequencing using the NGS platform. The differentially expressed genes (\>2 fold-change) were analyzed with Ingenuity^®^ Pathway Analysis (IPA) and the Database for Annotation, Visualization and Integrated Discovery (DAVID) for pathway analysis and functional interpretation. These dysregulated genes were additionally verified in representative Gene Expression Omnibus (GEO) datasets. The differentially expressed miRNAs (\>2 fold-change) were analyzed with miRmap (mirmap.ezlab. org) ([@b23-ijmm-43-04-1643]) for target prediction. Then, Venn diagrams were used to determine genes with potential miRNA-mRNA interactions. These potential miRNA-mRNA interactions were confirmed using a second miRNA prediction database, TargetScan ([www.targetscan.org](http://www.targetscan.org)) ([@b24-ijmm-43-04-1643]). Finally, a literature search for the functions of these dysregulated genes was performed, and a hypothesis was generated.

Culture of primary cells
------------------------

Diseased human lung fibroblasts (DHLF)-IPF (cat. no. CC-7231) and normal human lung fibroblasts (NHLF; cat. no. CC-2512) were purchased from Lonza Walkersville Inc. (Walkersville, MD, USA). The cells were grown in FGW™-2 Fibroblast Growth Medium-2 Bulletkit™ (Lonza Walkersville Inc.; cat. no. CC-3132), containing 0.5 ml human fibroblast growth factor-basic, 0.5 ml insulin, 10 ml fetal bovine serum and 0.5 ml GA-1000. To avoid losing any original characteristics over multiple generations, the DHLF-IPF and NHLF cells used for the NGS analysis were harvested from the 1st generation of cells following cultivation from the primary cells.

NGS
---

The expression profiles of miRNAs and mRNAs were examined using NGS. Protocol was described in our previous studies ([@b25-ijmm-43-04-1643]-[@b27-ijmm-43-04-1643]). In brief, total RNA from the DHLF-IPF and NHLF cells were extracted with TRIzol^®^ reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA) at Welgene Biotech Co., Ltd. (Taipei, Taiwan). Purified RNA was quantified at an optical density of 260 nm using an ND-1000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc.) and the RNA quality was examined using a Bioanalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA, USA) with RNA 6000 LabChip^®^ kit (Agilent Technologies, Inc.). Next, the samples were prepared for library construction and sequencing using an Illumina preparation kit (Illumina, Inc., San Diego, CA, USA). For small RNA sequencing, the harvested cDNA constructs containing 18-40-nucleotide RNA fragments (140-155 nucleotides in length with all adapters) were selected. The libraries were then sequenced on an Illumina instrument (75 single-end cycles). Following trimming and removal of reads with low quality scores using Trimmomatics ([@b28-ijmm-43-04-1643]), the qualified reads were analyzed with miRDeep2 ([@b29-ijmm-43-04-1643]) and the UCSC Genome Browser ([genome.ucsc.edu/](http://genome.ucsc.edu/)) ([@b30-ijmm-43-04-1643]). The miRNAs with low levels (\<1 normalized read per million) in either DHLF-IPF or NHLF cells were excluded.

For transcriptome sequencing, the library was constructed with a SureSelect Strand Specific RNA Library Preparation kit (Agilent Technologies, Inc.), and sequenced on a Solexa platform (150 paired-end cycles), using the TruSeq SBS kit (Illumina, Inc.). Similar with small RNA sequencing data, Trimmomatics (version 0.36) was implemented to trim or remove the reads with low quality score. Qualified reads were analyzed using HISAT2 (version 2.1.0) ([@b31-ijmm-43-04-1643]). The genes with low expression levels \[\<0.3 fragment per kilobase of transcript per million mapped reads (FPKM)\] in either DHLF-IPF or NHLF cells were excluded. The 2-tailed P-values were calculated \[2(Cufflinks version 2.2.1)\] with non-grouped samples used 'blind mode', in which all samples were treated as replicates of a single global 'condition' and used to build one model for statistical analysis ([@b32-ijmm-43-04-1643],[@b33-ijmm-43-04-1643]). Genes with P\<0.05 \[(-log~10~) P-value \>1.3\] and \>2 fold-changes were considered to be significantly dysregulated genes.

miRmap and TargetScan database analysis
---------------------------------------

miRmap is an open-source software library, which provides comprehensive miRNA-target prediction ([@b23-ijmm-43-04-1643]). By calculating the complementary ability of miRNA-mRNA interactions, the putative target genes of each miRNA may be identified. By combining thermodynamic, evolutionary, probabilistic and sequence-based features, the predictor also estimates mRNA-repression strength for ranking potential candidate targets. The prediction produces a list of putative target genes with an miRmap score, a predictive reference value. In the present study, an miRmap score ≥99 was used as the criterion for selecting putative miRNA targets.

TargetScan is an online database for predicting biological targets of miRNAs ([@b24-ijmm-43-04-1643]). It searches for the presence of conserved 8, 7 and 6 mer sites, which match the seed region of each miRNA. Predictions are ranked based on the predicted targeting efficacy or the probability of conserved targeting.

IPA
---

IPA (Qiagen Inc., Valencia, CA, USA) ([@b34-ijmm-43-04-1643]) is a web-based software application for the analysis, integration and interpretation of data derived from 'omics experiments, including RNA sequencing, small RNA sequencing, microarrays, metabolomics and proteomics. IPA enables the rapid understanding and visualization of data, and provides a range of data in addition to pathway analysis, including the identification of key regulators and activity to explain expression patterns, prediction of downstream effects on biological and disease processes, and provision of targeted data on genes, proteins, chemicals and drugs. The dysregulated genes from the IPF fibroblasts were uploaded to IPA (version 2.3) to identify the top canonical pathways, upstream regulators, and molecular and cellular functions.

DAVID database analysis
-----------------------

DAVID is a powerful gene functional classification tool that integrates multiple functional annotation databases, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes databases (<https://david.ncifcrf.gov/>) ([@b35-ijmm-43-04-1643],[@b36-ijmm-43-04-1643]). By calculating the similarity of global annotation profiles with an agglomeration algorithm method, a list of notable genes may be classified into clusters of associated 'Biological Process, 'Cellular Components', and 'Molecular Functions'. It also provides an Expression Analysis Systematic Explorer (EASE) score, a modified one-tailed Fisher's Exact P-value, for analysis. The reference score represents how specifically the user genes are involved in the category. An EASE score=0.1 was selected as the default, and =1 to extend clustering range in the analysis in the present study.

GEO database analysis
---------------------

The GEO is a web database that collects submitted high-throughput gene-expression data of microarrays, chips or NGS ([www.ncbi.nlm.nih.gov/geo](http://www.ncbi.nlm.nih.gov/geo)) ([@b37-ijmm-43-04-1643]). Microarrays of accession numbers GSE24206, which included whole lung tissue samples from patients with early and advanced IPF ([@b38-ijmm-43-04-1643]) and GSE44723, which included samples of cultured lung fibroblasts from patients with IPF ([@b39-ijmm-43-04-1643]), were used in the present study. GSE44723 assessed gene expression in fibroblasts obtained from 4 normal controls, 4 patients with rapidly progressing IPF and 6 patients with slowly progressing IPF. GSE24206 assessed gene expression in whole lung biopsy or explant samples from 6 healthy controls, 8 patients with early IPF and 9 patients with advanced IPF. The databases used the platform of Affymetrix Human Genome U133 Plus 2.0 Array. Raw data extracted from the GEO were replotted using GraphPad Prism 7 software (GraphPad Software, Inc., La Jolla, CA, USA).

Statistical analysis
--------------------

Statistical analyses were performed using SAS 9.4 software (SAS Institute Inc., Cary, NC, USA). To identify the differentially expressed genes, the Wilcoxon rank-sum test was used to compare gene expressions between two groups (patients with IPF vs. controls), and the Kruskal-Wallis test followed by Benjamini-Hochberg multiple-testing corrections was used to compare gene expressions across three groups. P\<0.05 was considered to indicate a statistically significant difference. Dysregulated genes identified from the IPF and normal fibroblasts NGS analysis were considered verified if they met the following criteria: Exhibiting concordant up-/downregulation in the GSE24206 and GSE44723 datasets, and demonstrating significantly different expression between patients with IPF and controls or across three groups in at least one dataset.

Results
=======

Gene expression profiles and miRNA changes in IPF fibroblasts
-------------------------------------------------------------

Samples from DHLF-IPF and NHLF cells were sequenced for mRNA and small RNA using an NGS platform. The volcano plot of dysregulated genes in fibroblasts of patients with IPF (DHLF-IPF cells) compared with normal controls (NHLF cells) is presented in [Fig. 2A](#f2-ijmm-43-04-1643){ref-type="fig"}. The red nodes represent the significantly upregulated genes, and the green nodes represent significantly downregulated genes. The density plot of the deep sequencing results between the DHLF-IPF and NHLF cells is presented in [Fig. 2B](#f2-ijmm-43-04-1643){ref-type="fig"}. The gene expression of DHLF-IPF cells demonstrated increased FPKM values and increased density compared with NHLF cells. Gene expression analysis revealed 42 differentially expressed genes with fold-change \>2, including 23 upregulated and 19 down-regulated genes ([Table I](#tI-ijmm-43-04-1643){ref-type="table"}). miRNA expression analysis revealed 60 miRNAs with fold-change \>2, including 43 upregulated and 17 downregulated miRNAs ([Table II](#tII-ijmm-43-04-1643){ref-type="table"}). According to miRmap analysis, 1,908 targets were predicted from these dysregulated miRNAs.

IPA and DAVID analysis of dysregulated genes in IPF fibroblasts
---------------------------------------------------------------

The pathways and functional annotation of the 42 dysregulated genes in IPF fibroblasts were first analyzed using IPA. The results are summarized in [Table III](#tIII-ijmm-43-04-1643){ref-type="table"}. The top canonical pathways were cAMP-mediated signaling, GP6 signaling pathway, cardiac-adrenergic signaling, hepatic fibrosis/hepatic stellate cell activation and calcium transport I. The top upstream regulators were fibrillin-1, bromodo-main-containing protein 4, transcription factor GATA-6, TSIX and DNA-binding protein RFX5. [Fig. 4](#f4-ijmm-43-04-1643){ref-type="fig"} demonstrates the network of these top 5 upstream regulators and dysregulated genes. The top molecular and cellular functions included cell cycle, cell morphology, cellular development, lipid metabolism and molecular transport.

The functional annotation of the 42 dysregulated genes was subsequently analyzed using DAVID. Notably, results within the 'Biological Process', 'Cellular Component' and 'Molecular Function' categories all indicated that the most significant function of these dysregulated genes was associated with the composition and function of the extracellular matrix (ECM) ([Fig. 3](#f3-ijmm-43-04-1643){ref-type="fig"}).

GEO database analysis of dysregulated genes in IPF fibro- blasts
----------------------------------------------------------------

To additionally verify the 42 dysregulated genes in clinical samples from patients with IPF, the GEO database was searched and two representative microarray datasets were selected: GSE44723 (IPF cultured lung fibroblasts) and GSE24206 (early and advanced IPF whole lung tissues). Dysregulated genes were considered verified if they exhibited concordant up-/downregulation in the two GSE44723 and GSE24206 datasets, with significantly different expression between patients with IPF and controls in at least one dataset. The results are summarized in [Table IV](#tIV-ijmm-43-04-1643){ref-type="table"}. Based on the GEO analysis, neurotrimin (*NTM*), paired box 8 (*PAX8*) and mesoderm development LRP chaperone (*MESD*) were verified as the upregulated genes, and ITPR interacting domain containing 2 (*ITPRID2*) and Inka box actin regulator 2 (*INKA2*) as the downregulated genes in IPF. The detailed expression levels of these 5 genes in each group were plotted and compared in [Fig. 5](#f5-ijmm-43-04-1643){ref-type="fig"}.

Identification of dysregulated genes with potential miRNA-mRNA interactions in IPF fibroblasts
----------------------------------------------------------------------------------------------

Venn diagram analysis of the 1,908 target genes of 60 dysregulated miRNAs, predicted from miRmap, and the 42 dysregulated genes revealed 5 dysregulated genes with potential miRNA-mRNA interactions in IPF fibroblasts ([Fig. 6](#f6-ijmm-43-04-1643){ref-type="fig"}). A total of 2 miRNA-mRNA interactions, *Homo sapiens* (hsa)-miR-185-3p-heat shock protein family A member 12B (*HSPA12B*) and hsa-miR185-3p-GRB associated binding protein 2 (*GAB2*), were excluded due to a lack of biological plausibility (the miRNA and mRNA were upregulated). The remaining 3 genes with miRNA-mRNA interactions were subsequently verified in a second miRNA predicting database, TargetScan. The results identified hsa-miR-185-3p-TRNA-YW synthesizing protein 1 homolog (*TYW1*), hsa-miR-3662- glycoprotein M6B (*GPM6B*), hsa-miR-1254-*INKA2* and hsa-miR-766-3p-*INKA2* as the potential miRNA-mRNA interactions in IPF fibroblasts ([Table V](#tV-ijmm-43-04-1643){ref-type="table"}).

Discussion
==========

The pathogenic mechanisms of IPF have not yet been fully elucidated. The hallmarks of IPF are aberrant activation of lung epithelial cells, accumulation of fibroblasts and myofibroblasts, and excessive production of ECM ([@b4-ijmm-43-04-1643],[@b14-ijmm-43-04-1643]-[@b16-ijmm-43-04-1643]). Previous data indicate that fibroblasts, as one of the key cells, serve a crucial role in the development and progression of IPF ([@b16-ijmm-43-04-1643]). An improved understanding of the gene regulation in IPF fibroblasts may assist in the development of novel therapeutics targeting this key cell. In the present study, the whole mRNA and miRNA profiles of IPF fibroblasts were obtained using an NGS platform, and bioinformatics analyses were performed in a step-wise manner. A total of 42 dysregulated genes were identified, and then bioinformatics tools IPA and DAVID were used for pathway and functional analyses. A total of 5 of the differentially expressed genes were verified in the representative GEO datasets, including *NTM*, *PAX8* and *MESD* (upregulated)*,* and *ITPRID2* and *INKA2* (downregulated). Integrated analysis of mRNA and miRNA expression data was also performed, and hsa-miR-185-3p-*TY W1*, hsa-miR-3662-*GPM6B*, hsa-miR-1254-*INKA2* and hsa-miR-766-3p-*INKA2* were identified as the potential miRNA-mRNA interactions in IPF fibroblasts. According to the GEO verification, hsa-miR-1254-*INKA2* and hsa-miR-766-3p-*INKA2* were considered as the most likely dysregulated miRNA-mRNA interactions in IPF fibroblasts. However, these interactions were identified based on bioinformatic analysis. Therefore, they require additional experiments to confirm the results. Hsa-miR185-3p-*HSPA12B* and hsa-miR185-3p-*GAB2* were excluded from subsequent analysis, as the miRNAs and mRNAs were dysregulated in the same manner. There is a possibility of indirect modulation, in that the upregulated hsa-miR185-3p may control one or more other targets. Which may in turn upregulate the expression levels of *HSPA12B* or *GAB2*. Nevertheless, the upregulated levels of *HSPA12B* or *GAB2* were not validated in the GEO database analysis. Whether these 2 miRNA-mRNA interactions were excluded or not did not affect the final results.

In the GO analysis, it was identified that the most important function of the identified dysregulated genes was associated with the composition and function of the ECM. Replacement of the normal lung structure with an excessive deposition of disorganized collagen and ECM is the hallmark of IPF ([@b40-ijmm-43-04-1643]). Although previous evidence suggests that fibroblasts and myofibroblasts in the fibrotic foci are the key cells leading to excessive ECM production ([@b41-ijmm-43-04-1643]), the crosstalk between epithelial cells, fibroblasts, myofibroblasts and ECM remains largely uncharacterized. The results from the present study improve the understanding of the fibroblast-ECM interaction in the pathogenesis of IPF. The development of novel therapeutic strategies targeting the fibrotic ECM may provide an opportunity to halt fibrosis and restore organ function ([@b42-ijmm-43-04-1643]). A recent study confirmed the importance of the ECM in IPF pathogenesis and treatment: Kwapiszewska *et al* ([@b43-ijmm-43-04-1643]) compared transcriptomic profiles in lung homogenates and fibroblasts obtained from patients with IPF treated with or without pirfenidone. They identified that cell migration-inducing and hyaluronan-binding protein (CEMIP) was markedly downregulated by pirfenidone treatment. They also identified that circulating CEMIP levels were significantly increased in patients with IPF compared with the healthy controls, and that pirfenidone treatment was associated with a significant decrease in CEMIP levels. CEMIP has been previously associated with ECM production, inflammation and cell proliferation ([@b44-ijmm-43-04-1643],[@b45-ijmm-43-04-1643]). They concluded that pirfenidone exhibited effects on multiple pathways in fibroblasts and other pulmonary cells, through the regulation of the ECM structure and inflammatory reactions.

The *INKA2* gene, also known as family with sequence similarity 212 member B or chromosome 1 open reading frame 183, encodes the protein serine/threonine-protein kinase PAK4 (PAK4)-inhibitor INKA2. The PAK4-inhibitor INKA proteins, with 2 isoforms in humans, are endogenous inhibitors of PAK4 ([@b46-ijmm-43-04-1643]). The PAK proteins are a family of serine/threonine cyclin-dependent kinase inhibitor 1-activating protein kinases and have been implicated in a range of biological activities ([@b46-ijmm-43-04-1643]). PAK4 is an effector molecule for the Rho GTPase cell division control protein 42 homolog. Previous experiments have indicated that active PAK4 protects cells from apoptosis ([@b47-ijmm-43-04-1643],[@b48-ijmm-43-04-1643]). PAK4 is associated with tumorigenesis and progression in different types of cancer through promoting cell growth, proliferation, migration and metastasis ([@b49-ijmm-43-04-1643]-[@b55-ijmm-43-04-1643]). The downregulation of *INKA2* identified in the present study may potentially upregulate the expression of *PAK4*, which in turn promotes cell proliferation and inhibits cell apoptosis in IPF fibroblasts. The NGS data suggested that the FPKM of *PAK4* was 0.2922 in IPF fibroblasts, but undetectable in normal lung fibroblasts. Based on the quality control criterion to exclude genes with FPKM \<0.3 in either IPF or normal fibroblasts, *PAK4* was not able to be analyzed in the present study. The upregulation of *PAK4* in IPF fibroblasts required additional confirmation. It was also identified that the miRNAs hsa-miR-1254 and hsa-miR-766-3p, 2 putative regulators of *INKA2*, were upregulated in IPF fibroblasts. Therefore, the results suggested that the miRNA-mRNA interaction in the *INKA2* gene may serve a role in cell growth, proliferation or apoptosis inhibition in IPF fibroblasts.

The *PAX8* gene encodes protein PAX8, which is a member of the paired box family of transcription factors. PAX8 is involved in the development and differentiation of thyroid follicular cells ([@b56-ijmm-43-04-1643],[@b57-ijmm-43-04-1643]), and is associated with the growth of cancer cells ([@b58-ijmm-43-04-1643],[@b59-ijmm-43-04-1643]). Overexpression of *PAX8* has been observed in a number of types of cancer. It also has a critical role in the survival and proliferation of epithelial cells ([@b60-ijmm-43-04-1643]). In the present study, upregulation of *PAX8* was identified in IPF fibroblasts. These data suggested that PAX8 may serve a role in promoting the growth, survival or proliferation of fibroblasts in IPF. The upregulation of *NTM* and *MESD* (also known as mesoderm development candidate 2), and downregulation of *ITPRID2* (also known as Ki-Ras-induced actin-interacting protein or sperm specific antigen 2) were also identified in IPF fibroblasts. Neurotrimin, a neural cell adhesion molecule, may promote neurite outgrowth and adhesion via a homophilic mechanism ([@b61-ijmm-43-04-1643],[@b62-ijmm-43-04-1643]). In addition to brain tissue, human tissue-specific expression analysis indicated a high expression of *NTM* in human lung tissue ([@b63-ijmm-43-04-1643]). MESD, a specialized chaperone for low-density lipoprotein receptor-related protein (LRP)5 and LRP6, is a universal inhibitor of Wnt/LRP signaling on the cell surface ([@b64-ijmm-43-04-1643],[@b65-ijmm-43-04-1643]). *ITPRID2* encodes a protein that is involved in the regulation of filamentous actin and extracellular signals ([@b66-ijmm-43-04-1643]), and may be associated with structural integrity and/or signal transductions in human cancer ([@b67-ijmm-43-04-1643]). The functions of *NTM*, *MESD* and *ITPRID2* remain largely unknown. Their associations with human lung diseases, particularly IPF, require additional investigation.

The identified gene dysregulation in fibroblasts and their proposed mechanisms in IPF are summarized in [Fig. 7](#f7-ijmm-43-04-1643){ref-type="fig"}. In summary, the present study demonstrated that *NTM*, *PAX8* and *MESD* were upregulated and *ITPRID2* and *INKA2* were downregulated in IPF fibroblasts. Dysregulation of *PAX8* and *INKA2* may participate in the regulation of proliferation and survival in IPF fibroblasts. Functional analysis of the dysregu-lated genes suggested a marked association between fibroblasts and ECM. The integrated analysis of miRNA and mRNA expression profiles suggested that the upregulated miRNAs hsa-miR-1254 and hsa-miR-766-3p may downregulate *INKA2* and serve important roles in IPF. These data improve the current understanding of fibroblasts as key cells in the pathogenesis of IPF. As a screening study using bioinformatics approaches, without biological or cross-platform replicates, the results of the present study require additional validation.
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![Schematic illustration of the study design. Following culture of the IPF fibroblasts and healthy lung fibroblasts, the total RNA were extracted and deep sequenced using a next-generation sequencing platform. The differentially expressed genes (\>2 fold-change) were identified, and analyzed with IPA and DAVID for pathway analysis and functional interpretation. The GEO IPF databases were analyzed to confirm dysregulated genes identified in the present study. Conversely, the differentially expressed miRNAs (\>2 fold-change) were analyzed with miRmap for target prediction. Then, genes with potential miRNA-mRNA interactions were determined by Venn diagram analysis. These miRNA-mRNA interactions were verified by a second miRNA prediction database, TargetScan. Finally, a literature search was performed and a hypothesis was generated. IPF, idiopathic pulmonary fibrosis; IPA, Ingenuity^®^ Pathway Analysis; DAVID, Database for Annotation, Visualization, and Integrated Discovery; GEO, Gene Expression Omnibus.](IJMM-43-04-1643-g00){#f1-ijmm-43-04-1643}

![Differential gene expression patterns between IPF and normal fibroblasts. (A) The volcano plot of -log~10~ (P-value) vs. log~2~ (fold-change) demonstrated differentially expressed genes in DHLF-IPF vs. NHLF. Genes with -log~10~ (P-value) \>1.3 and \>2 fold-changes are plotted in red (upregulated genes) or green (downregulated genes). (B) The frequency distribution of FPKM between DHLF-IPF cells and NHLF cells was compared and presented in the density plot. IPF, idiopathic pulmonary fibrosis; FPKM, fragments per kilobase of transcript per million mapped reads; DHLF, diseased human lung fibroblasts; NHLF, normal human lung fibroblasts.](IJMM-43-04-1643-g01){#f2-ijmm-43-04-1643}

![Gene Ontology analysis of dysregulated genes identified in idiopathic pulmonary fibrosis fibroblasts. Functional annotation of the 42 dysregulated genes was determined using Database for Annotation, Visualization, and Integrated Discovery. Results within the (A) Biological Process, (B) Cellular Component and (C) Molecular Function categories all indicated that the most significant function of these genes was associated with the composition and function of extracellular matrix.](IJMM-43-04-1643-g02){#f3-ijmm-43-04-1643}

![Network of top 5 upstream regulators and dysregulated genes in idiopathic pulmonary fibrosis fibroblasts. The top 5 upstream regulators, including FBN1, BRD4, GATA6, TSIX and RFX5, were generated using Ingenuity^®^ Pathway Analysis based on the significance of overlap between the dysregulated genes and the genes that were regulated by the upstream regulators. The dysregulated genes targeted by these top upstream regulators were *COL1A2, COL4A1* and *COL4A2*, all belonging to the fibrillar collagen family. Numbers in parentheses are the number of reports supporting interactions. E, expression; FC, expression fold-change; PD, protein-DNA binding; CLO1A2, collagen alpha-2(I) chain; COL4A1, collagen alpha-1(IV) chain; COL4A2, collagen alpha-2(IV) chain; FBN1, fibrillin-1; BRD4, bromodomain-containing protein 4; GATA6, transcription factor GATA-6; RFX5, DNA-binding protein RFX5.](IJMM-43-04-1643-g03){#f4-ijmm-43-04-1643}

![Gene Expression Omnibus analysis of 5 dysregulated genes in IPF fibroblasts. Representative microarray datasets GSE44723 (slowly and rapidly progressing IPF: cultured lung fibroblasts) and GSE24206 (early and advanced IPF: whole lung tissue) were used for verification of differential gene expressions identified from Next Generation Sequencing analysis. The results indicated that the expression of *INKA2* and *ITRPID2* were downregulated and *PAX8, MESD* and *NTM* were upregulated in IPF. Cultured lung fibroblasts and whole lung from healthy subjects were used as the normal controls. P-values were calculated using the Wilcoxon rank-sum test for comparisons of two groups, and the Kruskal-Wallis test for comparisons of three groups. Adjusted P-values were calculated using the Kruskal-Wallis test followed by Benjamini-Hochberg multiple-testing corrections. ^\*^Adjusted P\<0.05, ^\*\*^adjusted P\<0.01 and \*\*\*adjusted P\<0.001. IPF, idiopathic pulmonary fibrosis; INKA2, Inka box actin regulator 2; ITPRID2, ITPR interacting domain containing 2; PAX8, paired box 8; MESD, mesoderm development LRP chaperone; NTM, neurotrimin.](IJMM-43-04-1643-g04){#f5-ijmm-43-04-1643}

![Venn diagram analysis of miRNA-mRNA interactions in idiopathic pulmonary fibrosis fibroblasts. RNA sequencing revealed 42 dysregulated genes (left). Small RNA sequencing revealed 60 dysregulated miRNAs, which predicted 1,908 target genes (right) based on miRmap database. Venn diagram analysis identified 5 dysregulated genes with potential miRNA-mRNA interaction. miRNA, microRNA.](IJMM-43-04-1643-g05){#f6-ijmm-43-04-1643}

![Proposed mechanisms demonstrating gene regulations of fibroblasts and their potential roles in IPF. Upregulation of hsa-miR-1254 and hsa-miR-766-3p may inhibit *INKA2* expression, leading to overexpression of *PAK4*, which may promote fibroblast proliferation and migration, and protect fibroblasts from apoptosis. Overexpression of *PAX8* may also have a role in fibroblast proliferation. The functions of *NTM, MESD* and *ITPRID2* remain unknown. Whether they contribute to the pro-proliferative and pro-fibrotic microenvironment requires additional study. Based on the results of the Gene Ontology analysis, the gene dysregulations in IPF fibroblasts may also have a role in the excessive production and deposition of disorganized ECM. The hsa-miR-1254-*INKA2* and hsa-miR-766-3p-*INKA2* interactions were identified based on bioinformatic analysis, and therefore requires additional experiments to confirm. IPF, idiopathic pulmonary fibrosis; hsa, *Homo sapiens*; INKA2, Inka box actin regulator 2; PAK4, serine/threonine-protein kinase PAK4; PAX8, paired box 8; MESD, mesoderm development LRP chaperone; NTM, neurotrimin; ITPRID2, ITPR interacting domain containing 2; ECM, extracellular matrix.](IJMM-43-04-1643-g06){#f7-ijmm-43-04-1643}

###### 

Dysregulated gene in IPF fibroblasts compared with normal lung fibroblasts.

  A, Upregulated                                                                                              
  ------------------ -------------------------------------------------------------- -------- -------- ------- -------
  *HSPA12B*          Heat shock protein family A (Hsp70) member 12B                 59.62    3.28     18.18   0.005
  *NTM*              Neurotrimin                                                    117.08   8.40     13.94   0.032
  *PAX8*             Paired box 8                                                   86.90    13.69    6.35    0.000
  *MKI67*            Marker of proliferation Ki-67                                  16.75    3.25     5.15    0.045
  *POSTN*            Periostin                                                      42.91    8.35     5.14    0.024
  *MYO1C*            Myosin IC                                                      21.87    4.34     5.04    0.020
  *LINC01529*        Long intergenic non-protein coding RNA 1529                    41.54    12.83    3.24    0.007
  *COL1A2*           Collagen type I alpha 2 chain                                  69.47    23.42    2.97    0.015
  *CCNL1*            Cyclin L1                                                      38.61    13.41    2.88    0.031
  *ATP2B4*           ATPase plasma membrane Ca^2+^ transporting 4                   29.61    10.64    2.78    0.017
  *ANP32B*           Acidic nuclear phosphoprotein 32 family member B               52.75    19.24    2.74    0.037
  *PKMYT1*           Protein kinase, membrane associated tyrosine/threonine 1       571.51   212.09   2.69    0.032
  *GAB2*             GRB2-associated binding protein 2                              23.34    8.87     2.63    0.005
  *GPM6B*            Glycoprotein M6B                                               39.57    15.38    2.57    0.029
  *TDG*              Thymine DNA glycosylase                                        32.79    13.38    2.45    0.048
  *HSPA8*            Heat shock protein family A (Hsp70) member 8                   94.93    39.54    2.40    0.041
  *CD248*            CD248 molecule                                                 25.01    10.79    2.32    0.036
  *LINC00847*        Long intergenic non-protein coding RNA 847                     91.64    41.90    2.19    0.026
  *ANKRD18EP*        Ankyrin repeat domain 18E, pseudogene                          98.99    45.65    2.17    0.022
  *CNN3*             Calponin 3                                                     70.11    33.29    2.11    0.047
  *MESD*             Mesoderm development LRP chaperone                             93.66    44.85    2.09    0.028
  *IQGAP1*           IQ motif containing GTPase activating protein 1                45.40    22.51    2.02    0.023
  *LINC01291*        Long intergenic non-protein coding RNA 1291                    161.02   80.15    2.01    0.010
                                                                                                              
  B, Downregulated                                                                                            
                                                                                                              
  *TYW1*             tRNA-YW synthesizing protein 1 homolog                         24.22    146.89   -6.06   0.044
  *COL4A1*           Collagen type IV alpha 1 chain                                 4.11     23.87    -5.81   0.006
  *AKAP12*           A-kinase anchoring protein 12                                  4.24     23.09    -5.45   0.017
  *ITPRID2*          ITPR interacting domain containing 2                           4.96     23.91    -4.82   0.042
  *PRKAR1B*          Protein kinase cAMP-dependent type I regulatory subunit beta   30.41    131.62   -4.33   0.036
  *INKA2*            Inka box actin regulator 2                                     11.38    47.14    -4.14   0.006
  *AKAP2*            A-kinase anchoring protein 2                                   12.30    47.75    -3.88   0.002
  *GPR17*            G protein-coupled receptor 17                                  14.88    52.29    -3.51   0.008
  *FAM151A*          Family with sequence similarity 151 member A                   11.47    36.15    -3.15   0.018
  *UXT-AS1*          UXT antisense RNA 1                                            48.81    151.15   -3.10   0.028
  *IL17RC*           Interleukin 17 receptor C                                      8.18     23.55    -2.88   0.033
  *SPDYE6*           Speedy/RINGO cell cycle regulator family member E6             10.45    30.07    -2.88   0.037
  *MED31*            Mediator complex subunit 31                                    25.55    69.73    -2.73   0.041
  *FEM1B*            Fem-1 homolog B                                                14.77    35.13    -2.38   0.010
  *NCL*              Nucleolin                                                      19.51    45.91    -2.35   0.030
  *PTX3*             Pentraxin 3                                                    20.35    44.55    -2.19   0.042
  *OR7E12P*          Olfactory receptor family 7 subfamily E member 12 pseudogene   126.50   268.42   -2.12   0.013
  *SPON1*            Spondin 1                                                      16.93    34.91    -2.06   0.030
  *COL4A2*           Collagen type IV alpha 2 chain                                 12.65    25.46    -2.01   0.040

IPF, idiopathic pulmonary fibrosis; FPKM, fragments per kilobase of transcript per million mapped reads; DHLF, diseased human lung fibroblast; NHLF, normal human lung fibroblast.

###### 

Dysregulated miRNAs in IPF fibroblasts vs. normal lung fibroblasts.

  miRNA               DHLF-IPF Seq (norm)   NHLF Seq (norm)   Fold-change   Up/Down
  ------------------- --------------------- ----------------- ------------- ---------
  hsa-miR-10b-5p      3,357.09              317.7             10.57         Up
  hsa-miR-412-5p      50.6                  5.86              8.63          Up
  hsa-miR-329-3p      6.77                  1.69              4.01          Up
  hsa-miR-4661-5p     4.51                  1.17              3.85          Up
  hsa-miR-4521        17.7                  4.82              3.67          Up
  hsa-miR-3130-3p     3.8                   1.17              3.25          Up
  hsa-miR-369-3p      26.73                 8.34              3.21          Up
  hsa-miR-615-3p      11.17                 3.52              3.17          Up
  hsa-miR-766-3p      5.58                  1.82              3.07          Up
  hsa-miR-548am-5p    5.11                  1.69              3.02          Up
  hsa-miR-5000-3p     5.46                  1.82              3.00          Up
  hsa-miR-619-5p      3.44                  1.17              2.94          Up
  hsa-miR-486-5p      424.28                145.3             2.92          Up
  hsa-miR-493-5p      369.05                132.01            2.80          Up
  hsa-miR-3613-5p     10.45                 3.78              2.76          Up
  hsa-miR-625-3p      5.7                   2.08              2.74          Up
  hsa-miR-33b-5p      4.75                  1.82              2.61          Up
  hsa-miR-382-3p      14.49                 5.6               2.59          Up
  hsa-miR-379-3p      33.38                 13.55             2.46          Up
  hsa-miR-199b-5p     471.8                 192.86            2.45          Up
  hsa-miR-127-3p      292.67                120.67            2.43          Up
  hsa-miR-1254        2.79                  1.17              2.38          Up
  hsa-miR-543         31.95                 13.42             2.38          Up
  hsa-miR-549a        15.92                 6.91              2.30          Up
  hsa-miR-193a-3p     5.7                   2.48              2.30          Up
  hsa-miR-665         24.11                 10.56             2.28          Up
  hsa-miR-376c-3p     20.55                 9.12              2.25          Up
  hsa-miR-487a-3p     32.9                  14.99             2.19          Up
  hsa-miR-582-3p      4.87                  2.22              2.19          Up
  hsa-miR-134-5p      174.73                80.14             2.18          Up
  hsa-miR-1185-5p     3.68                  1.69              2.18          Up
  hsa-miR-493-3p      159.05                73.89             2.15          Up
  hsa-miR-136-3p      424.16                198.72            2.13          Up
  hsa-miR-136-5p      12.35                 5.86              2.11          Up
  hsa-miR-1185-1-3p   49.06                 23.33             2.10          Up
  hsa-miR-654-3p      1,401.49              669.93            2.09          Up
  hsa-miR-185-3p      6.18                  3                 2.06          Up
  hsa-miR-548ao-3p    2.14                  1.04              2.06          Up
  hsa-miR-668-3p      3.21                  1.56              2.06          Up
  hsa-miR-410-3p      865.2                 424.42            2.04          Up
  hsa-miR-409-3p      3,074.39              1,512.26          2.03          Up
  hsa-miR-494-3p      6.3                   3.13              2.01          Up
  hsa-miR-1197        7.84                  3.91              2.01          Up
  hsa-miR-182-5p      47.63                 95.52             −2.01         Down
  hsa-miR-422a        1.66                  3.39              −2.04         Down
  hsa-miR-3200-3p     3.8                   7.95              −2.09         Down
  hsa-miR-335-5p      49.53                 103.99            −2.10         Down
  hsa-miR-138-1-3p    87.18                 189.86            −2.18         Down
  hsa-miR-365a-5p     1.43                  3.13              −2.19         Down
  hsa-miR-5699-5p     1.07                  2.35              −2.20         Down
  hsa-miR-664a-3p     2.38                  5.86              −2.46         Down
  hsa-miR-1538        2.26                  5.6               −2.48         Down
  hsa-miR-4662a-5p    2.97                  7.56              −2.55         Down
  hsa-miR-335-3p      341.14                920.39            −2.70         Down
  hsa-miR-29c-5p      1.19                  3.39              −2.85         Down
  hsa-miR-9-5p        1.54                  4.69              −3.05         Down
  hsa-miR-4461        2.61                  7.95              −3.05         Down
  hsa-miR-3662        1.43                  4.82              −3.37         Down
  hsa-miR-4767        1.31                  4.82              −3.68         Down
  hsa-miR-204-5p      45.37                 170.97            −3.77         Down

IPF, idiopathic pulmonary fibrosis; DHLF, diseased human lung fibroblast; NHLF, normal human lung fibroblast; Up, upregulation; Down, downregulation; hsa, *Homo sapiens*; miR, microRNA.

###### 

Summary of Ingenuity^®^ Pathway Analysis of 42 dysregulated genes in idiopathic pulmonary fibrosis fibroblasts.

  Categories                                           P-value         Overlap (%)   No. of molecules
  ---------------------------------------------------- --------------- ------------- ------------------
  Top canonical pathways                                                             
   cAMP-mediated signaling                             0.0007          4/225 (1.8)   \-
   GP6 signaling pathway                               0.0018          3/131 (2.3)   \-
   Cardiac-adrenergic signaling                        0.0021          3/140 (2.1)   \-
   Hepatic fibrosis/hepatic stellate cell activation   0.0045          3/183 (1.6)   \-
   Calcium transport I                                 0.0181          1/10 (10.0)   \-
  Top upstream regulators                                                            
   FBN1                                                0.0002          \-            \-
   BRD4                                                0.0021          \-            \-
   GATA6                                               0.0030          \-            \-
   TSIX                                                0.0037          \-            \-
   RFX5                                                0.0037          \-            \-
  Top molecular and cellular function                                                
   Cell cycle                                          0.0013-0.0181   \-            6
   Cell morphology                                     0.0018-0.0395   \-            4
   Cellular development                                0.0018-0.0106   \-            4
   Lipid metabolism                                    0.0018-0.0199   \-            2
   Molecular transport                                 0.0018-0.0055   \-            2

IPA, Ingenuity^®^ Pathway Analysis; IPF, idiopathic pulmonary fibrosis; FBN1, fibrillin-1; BRD4, bromodomain-containing protein 4; GATA6, transcription factor GATA-6; RFX5, DNA-binding protein RFX5.

###### 

Gene Expression Omnibus verification of 42 dysregulated genes in IPF fibroblasts.

  A, Upregulated genes                                   
  ------------------------ ------- ------ ------- ------ ---------
  *HSPA12B*                18.15   N/A    \-      Up     0.835
  *NTM*                    13.94   Up     0.257   Up     0.010
  *PAX8*                   6.35    Up     0.341   Up     0.032
  *MKI67*                  5.15    Down   0.582   Up     0.017
  *POSTN*                  5.14    Down   0.688   Up     0.008
  *MYO1C*                  5.04    Down   0.810   Up     0.259
  *LINC01529*              3.24    N/A    \-      N/A    \-
  *COL1A2*                 2.97    Down   0.397   Up     \<0.001
  *CCNL1*                  2.88    Up     0.737   Down   \<0.001
  *ATP2B4*                 2.78    Up     0.147   Up     0.159
  *ANP32B*                 2.74    Up     0.443   Down   0.159
  *PKMYT1*                 2.69    Down   0.929   Up     0.832
  *GAB2*                   2.63    Down   0.873   Down   \<0.001
  *GPM6B*                  2.57    Up     0.890   Down   0.013
  *TDG*                    2.45    N/A    \-      Down   0.113
  *HSPA8*                  2.40    N/A    \-      Up     0.081
  *CD248*                  2.32    Down   0.255   Up     0.115
  *LINC00847*              2.19    Down   0.053   Up     0.091
  *ANKRD18EP*              2.17    N/A    \-      N/A    \-
  *CNN3*                   2.11    N/A    \-      Down   0.095
  *MESD*                   2.09    Up     0.958   Up     0.002
  *IQGAP1*                 2.02    Up     0.437   Down   0.717
  *LINC01291*              2.01    N/A    \-      N/A    \-
                                                         
  B, Downregulated genes                                 
                                                         
  *TYW1*                   -6.06   Up     0.201   Down   0.716
  *COL4A1*                 -5.81   Down   0.224   Up     0.354
  *AKAP12*                 -5.45   Up     0.410   Down   0.004
  *ITPRID2*                -4.82   Down   0.019   Down   0.031
  *PRKAR1B*                -4.33   Down   0.194   Up     0.767
  *INKA2*                  -4.14   Down   0.213   Down   0.001
  *AKAP2*                  -3.88   N/A    \-      Down   0.007
  *GPR17*                  -3.51   N/A    \-      Down   0.460
  *FAM151A*                -3.15   N/A    \-      Down   0.081
  *UXT-AS1*                -3.10   N/A    \-      N/A    \-
  *IL17RC*                 -2.88   Down   0.841   Down   0.630
  *SPDYE6*                 -2.88   N/A    \-      Down   0.220
  *MED31*                  -2.73   Up     0.478   Up     0.831
  *FEM1B*                  -2.38   Up     0.873   Down   0.024
  *NCL*                    -2.35   N/A    \-      Down   0.166
  *PTX3*                   -2.19   Up     0.918   Down   \<.001
  *OR7E12P*                -2.12   N/A    \-      Down   0.937
  *SPON1*                  -2.06   Up     0.986   Down   0.036
  *COL4A2*                 -2.01   Down   0.214   Up     0.584

Fold-change indicates the results of RNA-seq analysis from the next-generation sequencing data. GEO, Gene Expression Omnibus; IPF, idiopathic pulmonary fibrosis; N/A, not available.

###### 

Dysregulated genes with potential miRNA-mRNA interaction in IPF fibroblasts.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene      Gene full name                           mRNA fold-change   miRNA            miRNA fold-change   miRmap score   TargetScan Total context++ score
  --------- ---------------------------------------- ------------------ ---------------- ------------------- -------------- ----------------------------------
  *TYW1*    tRNA-YW synthesizing protein 1 homolog   -6.06              hsa-miR-185-3p   2.06                99.12          -0.37

  *GPM6B*   glycoprotein M6B                         2.44               hsa-miR-3662     -3.37               99.81          -0.09

  *INKA2*   Inka box actin regulator 2               -4.14              hsa-miR-1254\    2.38\               99.28\         -0.32\
                                                                        hsa-miR-766-3p   3.07                99.09          -0.67
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

IPF, idiopathic pulmonary fibrosis; miRNA, microRNA; hsa, *Homo sapiens*; TYW1, TRNA-YW synthesizing protein 1 homolog; GPM6B, glycoprotein M6B; INKA2, Inka box actin regulator 2.
